User:Mr. Ibrahem/Maraviroc

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Maraviroc
Structural formula of maraviroc
Ball-and-stick model of the maraviroc molecule
Clinical data
Pronunciation/məˈrævɪrɒk/ mə-RAV-i-rok Selzentry: /sɛlˈzɛntri/ sel-ZEN-tree
Trade namesSelzentry, Celsentri
Other namesUK-427857, 4,4-Difluoro-N-[(1S)-3-{(1R,3s,5S)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl}-1-phenylpropyl]
cyclohexanecarboxamide
AHFS/Drugs.comMonograph
MedlinePlusa607076
License data
Pregnancy
category
  • AU: B1
Routes of
administration		By mouth (tablets, oral solution)
Drug classCCR5 receptor antagonist[1]
Legal status
Legal status
Pharmacokinetic data
Bioavailability23%[3]
Protein binding~76%[4]
MetabolismLiver (CYP, predominantly CYP3A)[4]
MetabolitesSecondary amine formed by N-dealkylation (major)
Elimination half-life14–18 hours[4] (mean 16 hours)[5]
ExcretionFeces (76%), urine (20%)[4]
Identifiers
  • 4,4-Difluoro-N-{(1S)-3-[3-(3-isopropyl- 5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}cyclohexanecarboxamide
Chemical and physical data
FormulaC29H41F2N5O
Molar mass513.678 g·mol−1
3D model (JSmol)
  • Cc5nnc(n5[C@@H]1C[C@H]4CC[C@@H](C1)N4CC[C@H](NC(=O)C2CCC(F)(F)CC2)c3ccccc3)C(C)C
  • InChI=1S/C29H41F2N5O/c1-19(2)27-34-33-20(3)36(27)25-17-23-9-10-24(18-25)35(23)16-13-26(21-7-5-4-6-8-21)32-28(37)22-11-14-29(30,31)15-12-22/h4-8,19,22-26H,9-18H2,1-3H3,(H,32,37)/t23-,24+,25-,26-/m0/s1 ☒N
  • Key:GSNHKUDZZFZSJB-QYOOZWMWSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Maraviroc, sold under the brand names Selzentry and Celsentri, is an antiretroviral medication used to treat and prevent HIV/AIDS.[6] It is generally only recommended in cases which have CCR5 tropism and is not usually an initial treatment.[6] It is taken by mouth.[6]

Common side effects include cough, fever, rash, and upper respiratory tract infection.[6] Other side effects may include autoimmune disorders, allergic reactions, osteonecrosis, and liver problems.[6][1] Use is not typically recommended in pregnancy.[6] It should not be used in people with significant kidney problems.[6] It is in the CCR5 receptor antagonist and works by preventing HIV from entering cells.[1][7]

Maraviroc was approved for medical use in the United States and Europe in 2007.[6][7] In the United Kingdom it costs the NHS about £520 per month as of 2021.[1] This amount in the United States costs about 1,500 USD.[8]

References[edit]

  1. ^ a b c d BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 699. ISBN 978-0857114105.
  2. ^ "Celsentri EPAR". European Medicines Agency (EMA). Archived from the original on 12 November 2020. Retrieved 31 July 2020.
  3. ^ Abel S, Russell D, Whitlock LA, Ridgway CE, Nedderman AN, Walker DK (April 2008). "Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects". British Journal of Clinical Pharmacology. 65 (Suppl 1): 60–7. doi:10.1111/j.1365-2125.2008.03137.x. PMC 2311408. PMID 18333867.
  4. ^ a b c d "Selzentry- maraviroc tablet, film coated Selzentry- maraviroc solution". DailyMed. 18 July 2018. Archived from the original on 25 March 2021. Retrieved 31 July 2020.
  5. ^ Abel S, Back DJ, Vourvahis M (2009). "Maraviroc: pharmacokinetics and drug interactions". Antiviral Therapy. 14 (5): 607–18. PMID 19704163.
  6. ^ a b c d e f g h i j "Maraviroc Monograph for Professionals". Drugs.com. Archived from the original on 26 May 2016. Retrieved 14 November 2021.
  7. ^ a b "Celsentri". Archived from the original on 12 November 2020. Retrieved 14 November 2021.
  8. ^ "Maraviroc Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 23 July 2021. Retrieved 14 November 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Maraviroc&oldid=1211259067"